MetaCap

Lipocine (LPCN) vs Quoin Pharmaceuticals (QNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lipocine (LPCN) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 53.2% versus a loss of 82.1%. Over five years, LPCN leads with a -92.3% price change compared with -100.0% for QNRX. Lipocine is the larger company by market cap ($16.4 million vs $15.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LPCN-53.16%QNRX-82.07%
+273%+87%-99%
Nov 21, 20251 yearNov 20, 2026
LPCN-92.56%QNRX-99.99%
+66%-21%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LPCN versus QNRX key metrics
MetricLPCNQNRX
Share price$1.48$3.28
Market cap$16.39M$15.76M
1-day change-1.33%-2.35%
YTD return-81.57%-77.27%
1-year return-53.16%-82.07%
5-year return-92.30%-99.99%
P/E ratio (TTM)—7.45
EPS (TTM)$-1.32$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.98M—
Revenue growth (YoY)-82.35%—
Net income (latest FY)$-9.63M$-15.80M
Operating margin-524.69%—
Net margin-487.06%—
52-week high$12.37$23.50
52-week low$1.36$3.18
Distance from 52-week high-88.04%-86.04%
Analyst consensusnonenone
Avg. price target upside+237.84%+565.55%
Average volume1.84M541.26K
Shares outstanding11.07M4.80M
Employees144
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LPCN has outperformed QNRX by 28.9 percentage points over the past year.

About Lipocine

LPCN stock →

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

LPCN vs QNRX FAQ

Which is bigger, Lipocine or Quoin Pharmaceuticals?

Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.76M for Quoin Pharmaceuticals (QNRX).

Which stock has performed better over the past year, LPCN or QNRX?

LPCN returned -53.16% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.

Are Lipocine and Quoin Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons